Edetate Disodium as a Polysorbate Degradation and Monoclonal Antibody Oxidation Stabilizer.

Polysorbates are frequently used in biotherapeutic formulations. Interest in assessing their stability, in particular the impact of their degradation products on the stability of therapeutic proteins, has been steadily growing in the past decade. The work presented summarizes a case study of a monoclonal antibody formulation that demonstrated a simultaneous loss of polysorbate and an increase in methionine oxidation. Spiking studies were conducted to determine both the cause and a potential mitigation for the monoclonal antibody (mAb) oxidation and polysorbate 80 (PS80) loss. The results indicated that a different source material exhibited different rates of mAb oxidation and PS80 loss and that in all evaluated materials, the addition of edetate disodium to the formulation mitigated both observed issues. The mAb was assessed for the presence of lipases and lipoprotein lipase was detected at low levels. It is proposed that edetate disodium was effective in mitigating the mAb oxidation and PS80 loss by chelating calcium in the formulation and therefore decreasing the activity of the lipases.

[1]  Bo Zhang,et al.  Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody. , 2010, Journal of pharmaceutical sciences.

[2]  J. Agalloco,et al.  Validation of Pharmaceutical Processes , 2007 .

[3]  Steven R Labrenz,et al.  Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations. , 2014, Journal of pharmaceutical sciences.

[4]  Hanns-Christian Mahler,et al.  The Degradation of Polysorbates 20 and 80 and its Potential Impact on the Stability of Biotherapeutics , 2011, Pharmaceutical Research.

[5]  C. Kevil.  Catalase as a regulator of reactive sulfur metabolism; a new interpretation beyond hydrogen peroxide✩☆ , 2017, Redox Biology.

[6]  B. Kerwin.  Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. , 2008, Journal of pharmaceutical sciences.

[7]  R. Mogg,et al.  Measurement and decomposition kinetics of residual hydrogen peroxide in the presence of commonly used excipients and preservatives. , 2009, Journal of pharmaceutical sciences.

[8]  A. Pappenberger,et al.  Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis. , 2011, Journal of pharmaceutical sciences.

[9]  Wei Wang,et al.  Peroxide formation in polysorbate 80 and protein stability. , 2002, Journal of pharmaceutical sciences.

[10]  M. Klotz,et al.  The molecular evolution of catalatic hydroperoxidases: evidence for multiple lateral transfer of genes between prokaryota and from bacteria into eukaryota. , 2003, Molecular biology and evolution.

[11]  Chung C. Hsu,et al.  Site-Specific Tryptophan Oxidation Induced by Autocatalytic Reaction of Polysorbate 20 in Protein Formulation , 2011, Pharmaceutical Research.

[12]  F. J. Alvarez,et al.  The Role of Calcium Ions and Bile Salts on the Pancreatic Lipase-Catalyzed Hydrolysis of Triglyceride Emulsions Stabilized with Lecithin , 1989, Pharmaceutical Research.

[13]  G. Olivecrona,et al.  Calcium Triggers Folding of Lipoprotein Lipase into Active Dimers* , 2005, Journal of Biological Chemistry.

[14]  C. Schöneich,et al.  Biotherapeutic Formulation Factors Affecting Metal Leachables from Stainless Steel Studied by Design of Experiments , 2012, AAPS PharmSciTech.

[15]  Ankit Patel,et al.  Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway , 2015, Pharmaceutical Research.

[16]  Kelvin H. Lee,et al.  Knockout of a difficult‐to‐remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations , 2017, Biotechnology and bioengineering.

[17]  Hanns-Christian Mahler,et al.  Key interactions of surfactants in therapeutic protein formulations: A review. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  E. Maggio.  Use of excipients to control aggregation in peptide and protein formulations , 2010 .

[19]  Daniel Thomas,et al.  Biooxidation of n‐hexanol by alcohol oxidase and catalase in biphasic and micellar systems without solvent , 2003, Biotechnology and bioengineering.

[20]  A. Svendsen,et al.  Biochemical properties of cloned lipases from the Pseudomonas family. , 1995, Biochimica et biophysica acta.

[21]  Sandeep Yadav,et al.  Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations. , 2015, Molecular pharmaceutics.

[22]  Lihua Huang,et al.  Polysorbates 20 and 80 Degradation by Group XV Lysosomal Phospholipase A2 Isomer X1 in Monoclonal Antibody Formulations. , 2016, Journal of pharmaceutical sciences.

[23]  D. Mcclements,et al.  Role of calcium and calcium-binding agents on the lipase digestibility of emulsified lipids using an in vitro digestion model , 2010 .

[24]  E. Maggio,et al.  Polysorbates, peroxides, protein aggregation, and immuno- genicity - a growing concern. , 2012 .